By: Brittany Lovely From: onclive.com The surge of treatment options for patients with ovarian cancer poses a daunting challenge as answers for optimal sequencing continue to elude clinicians. Bevacizumab (Avastin) continues to hold the most utility in this disease setting, but the addition of PARP inhibitors, and immunotherapy raises the question of how to best deliver efficient regimens to patients. …
-
-
Love After a Breast Cancer Diagnosis
-
Why I Can’t Write Your Breast Cancer Story for You
-
Moving to a Distant Location as a Breast Cancer Survivor
-
Getting a Second Opinion After a Breast Cancer Diagnosis
-
Dealing with the Side Effects of Breast Cancer Treatments
